Telazoparib vs physicians choice for patients with mBRCA1 breast cancer

Dr Jennifer Litton speaks with ecancer at SABCS 2017 about the EMBRACA trial of telazoparib vs physicians choice for patients with mBRCA1 breast cancer.
With some patients still receiving treatment, Dr Litton reports on the improvements in both survival and quality of life for patients receiving telozoparib, noting a manageable toxicity profile with a slight risk of grade 1 alopecia.
She outlines further trials of telozoparib, and considers the future of PARP inhibitors in breast cancer treatment.